Major breakthrough alert! The FDA just approved the first-ever KRAS inhibitor (adagrasib, aka Krazati) for advanced colon cancer. This is huge for patients with the KRAS G12C mutation who’ve already tried other chemo options. The approval is based on a trial where about a third of patients saw their tumors shrink—finally, a new targeted option! If you or someone you know is fighting colon cancer, ask about molecular testing. Science is moving fast! #Health #BodyHealth #CancerBreakthrough